We invite all our readers to take part in our Hybridan Newsletters
and Equity Research Survey by clicking on the link: here
* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
Potential IPOs:***
21 May: Coastal Africa Group, a newly formed incorporated Company focused on acquiring and investing in the oil and gas sector, energy infrastructure, energy services and energy assets across West Africa, has announced its intention to IPO onto AIM. The expected Admission date is anticipated early June 2026.
17 March: Vista Parcs Group has announced its intention to IPO onto AIM. The newly incorporated entity is proposing to acquire a portfolio of 13 UK-based holiday and residential parks currently owned by Barney Group 2 Ltd (BG2) and operated by Baslow Parks Ltd. Deal details TBC and expected Admission date anticipated late June 2026.
Reverse Transactions:***
19th December 2025: Talon Resources (TAR.L), previously Medcaw Investments, the Company focused on identifying and acquiring prospective mining projects in the precious metals sector, with a primary focus on gold and other high-value commodities announced that it has entered into binding heads of terms (which includes an exclusivity agreement until 31 October 2026) with Ulvestone Ltd in respect of the proposed acquisition by the Company of 90% of the legal and beneficial interest in certain mineral exploration licences located in Ontario, Canada. The aggregate consideration payable by Medcaw is £4.17m, to be satisfied £70k in cash on execution of the definitive share purchase agreement, £100k in cash on AIM Admission, and £4m satisfied through the issue of new ordinary shares in Medcaw at a price of 1.5p per share, to be issued on AIM Admission. The indicative timetable in relation to the Cancellation and proposed re-admission to trading on AIM has been revised and is now expected to take effect on 23 June.
Market Movers:***
1st June: Mendell Helium (AQSE: MDH), the helium production company with operations in Kansas, announced its intention to move to AIM. The Company's ordinary shares are expected to commence trading on AIM during the week beginning 15 June 2026. No new Ordinary Shares are being issued or allotted in conjunction with admission to trading on AIM. Anticipated market capitalisation on Admission will be approximately £15m.
Banquet Buffet****
London Stock Exchange: Main Market and AIM
CPP Group 62.5p £5.6m (CPP.L)
The provider of real-time, digitally delivered assistance products which reduce disruptions to everyday life reports for the FY December 2025. Revenue was 14.7% lower at £2.1m with administration costs 10.6% lower at £9.3m. This gave a reduced loss before tax of £7.4m compared to £8.4m in 2024. The EBITDA loss is 21.4% lower at £5.2m and net cash is £5.6m which is down from £9.6m in 2024. The disposals of CPP Turkey and CPP India, materially simplified the Group and completed its transition away from legacy international operations. The purchaser of CPP India has stated that it does not intend to pay the outstanding $5.0m deferred consideration. The Group strongly disputes this position although the non-receipt of these proceeds has had a material impact on the Group's liquidity position. The Board has advanced discussions with existing and prospective investors regarding a refinancing package intended to support the Group's next phase of growth.
GCP Asset Backed Income Fund 65.9p £113.3m (GABI.L)
The closed-ended investment company announced that it has exchanged contracts for the sale of a portfolio of three senior loans secured against operational care home projects in the UK at a value that is in line with the value of such loans incorporated into the most recently published net asset value of the Company. The total proceeds expected to be received by the Company from completion of the Disposal is at least £41.4m. Completion is subject only to the effluxion of a 10-business day funding window and therefore the proceeds of the Disposal are expected to be received mid-June. The Company is due to publish its net asset value for 30 June 2026 in mid-July.
Gelion 21p £48.2m (GELN.L)
The Sulfur battery company reports a three-year collaborative project entitled Cost-effective, Resilient Solid-state Li-S. The project is alongside Nissan Technical Centre Europe and the University of Oxford, commencing in June 2026. The total project cost is £3.4m, with £2.4m being met in a combination of grant funding from Innovate UK across the partners including an award of £1.6m to Gelion's UK subsidiary. Gelion is seeking to replace the strategic minerals in current Lithium-ion battery cathodes with Gelion's Nano-Encapsulated Sulfur (NES) that are low cost and can be dropped into existing global manufacturing lines and is free from supply chain constraints. The grant will inform future scale-up, manufacturing and commercialisation efforts for solid-state batteries, with potential to expand collaboration across the automotive and energy storage sectors.
Great Southern Copper 2.7p £20.8m (GSCU.L)
The company focused on copper-gold-silver exploration in Chile announced that scout Reverse circulation drilling has commenced at the Victoria porphyry copper target at the Especularita Project, located at the southern margin of the La Colorada lithocap, with four holes planned to test high-grade vein and disseminated type mineralisation identified in outcrop. Rock chip geochemistry results have produced grades of up to 6.9% Cu, 1.85g/t Au and 84.8g/t Ag. The company also completed drilling recently at the nearby Artemisa North target which has confirmed evidence of a strong porphyry copper-style alteration system.
Inspiration Healthcare 26.2p £23.5m (IHC.L)
The global medical technology company, announces that on 1 June 2026 it entered into a framework agreement with Micrel Medical Devices SA for the transfer of the distribution of Micrel's infusion products to an entity controlled by Micrel effective from 31 January 2027. The Group has been the exclusive distributor of Micrel's ambulatory infusion pumps and related consumables in the United Kingdom since 2011. The infusion products generated revenue of £9.7m (unaudited) at a contribution margin of approximately 25% for the Group in the year ended 31 January 2026. Under the terms of the framework agreement, the existing distribution agreement will expire on 31 January 2027 with Micrel taking full control for the sale and distribution of the products in the UK. The Board expects these savings, combined with the compensation payment, to contribute to reducing net debt by approximately 20% during FY27.
Itaconix 120p £16.2m (ITX.L)
The innovator in high-performance plant-based specialty polymers, reports that trading in the current year has continued in line with the Board's expectations. The management expects H1 FY2026 will be another record half. The Board remains confident in the Company's strategy, customer pipeline and long-term growth opportunities. The Itaconix Performance Ingredients business continues to build momentum in consumer detergent applications for scale inhibition and odour neutralisation, supported by increasing customer adoption of safer, higher-performing and more sustainable ingredients. The Board continue to see encouraging activity levels from major customers and are closely tracking reorder rates from new customers to assess expected growth in 2026.
Panther Metals 140p £12.2m (PALM.L)*
The exploration company focused on mineral projects in Canada, updated for the ongoing drill programme at the Awkward Conduit Target, within the Obonga Project located upon the Obonga Greenstone Belt, Ontario, Canada. The drilling programme has been specifically designed to test the Company's geological model by targeting the interpreted base of a potentially tube-like magma conduit system, or chonolith, modelled as the magmatic feeder to the Awkward Intrusion, which hosts anomalous levels of nickel (Ni), copper (Cu) and platinum group metals. Portable XRF readings from sulphide-rich intervals returned elevated anomalous nickel and cobalt values, with sulphides visually dominated by pyrrhotite.
Verici Dx 0.45p £6.8m (VRCI.L)
The developer of advanced clinical diagnostics for organ transplant announced the publication of a health economic cost impact analysis demonstrating the significant potential cost benefit of the Pre-Transplant Risk Assessment (PTRA) test for predicting early acute rejection (EAR) in kidney transplant. The study, titled 'Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients' was conducted by Avalon Health Economics and has been published in the Journal of Health Economics and Outcomes Research. The study shows that integrating PTRA into standard clinical practice could generate substantial healthcare savings while also supporting more personalised immunosuppression strategies for patients. Key findings of the study include the potential for more than $191m in healthcare savings across the U.S. standard-risk kidney transplant population over two years.
Aquis Market:
Ethtry 0.195p £4.5m (AQSE: ETHY)
The UK-listed company which has implemented an Ethereum Treasury Policy to support the development and operation of its commercial and investment activities, announced that it has purchased a further 108.3253 Ethereum (ETH) as part of the ongoing execution of its treasury strategy. The Company has purchased 108.3253 ETH at a limit price of GBP 1,500 per ETH, representing a total consideration of approximately GBP 162,488. Following this purchase, Ethtry now holds a total of 925 ETH on its balance sheet.
The Board believes this further strengthens Ethtry's Ethereum treasury position and reflects its continued conviction in ETH as a core strategic reserve asset. The Company intends for the additional ETH acquired pursuant to this purchase to be incorporated into its treasury strategy, including staking where appropriate, in line with the Company's existing Ethereum Treasury Policy and risk management framework.
Sterling Digital 4.25p £6.4m (AQSE:ASIC)
The company established to develop low-energy-cost digital asset mining operations in the United States, updated with respect to the development of its mining site. On 1 June 2026, the Company entered into a contract with Terra Solis Mining LLC, for the pending commissioning and installation support of the Company's first gas to energy site. Terra Solis, based in Texas, specialises in installing and running industrial scale sites that convert natural gas to energy in line with the Company's business plan. Under the terms of the agreement, Terra Solis will establish the Company's phase 1 infrastructure and has been commissioned for the work at a materially lower cost than competitors. The company also reported it has opened a Bitcoin custodian account with Coinbase
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
